Scancell has reported robust Phase 2 data for its next-generation DNA vaccine iSCIB1+ in advanced melanoma, confirmed plans to accelerate into randomized registration-path studies in 2026, and outlined a tighter corporate strategy spanning immunotherapies and partnered antibodies. In the SCOPE trial, iSCIB1+ combined with ipilimumab and nivolumab delivered an 11-month progression-free survival of 78% in a predefined HLA target population, versus a historic 12-month PFS of 46% for the checkpoint doublet alone. Pooled across relevant cohorts, 22-month PFS reached 69% with favorable safety, prompting selection of iSCIB1+ as the lead asset, broadening the addressable population to roughly 80% of late-stage melanoma and extending patent life to 2039. Scancell also reported early Phase 2 signals for its Moditope candidate, Modi-1, in head and neck cancer when combined with pembrolizumab, while a second Genmab license on its GlyMab antibodies added nondilutive capital and external validation.
The bigger signal is strategic: off-the-shelf, HLA-directed vaccination layered onto checkpoint backbones is edging from concept to competitive reality. If randomized data reproduce these PFS gains without adding toxicity, first-line melanoma standards could shift again, this time toward vaccine-enabled regimens. The question is whether a mid-cap UK biotech can finance and execute a global registrational program alone at the pace the market now demands, or whether a co-development partner becomes the gating factor to lock in timing and scale before larger players cement the next checkpoint-era incumbency.
For patients and clinicians, the appeal is tangible. The regimen’s safety profile matters in a setting long dominated by efficacy-toxicity trade-offs, and practicalities such as -20°C storage and PharmaJet’s needle-free delivery lower barriers to adoption. HLA typing, while routine in many centers, still requires workflow integration; Medical Affairs will need to drive biomarker education, define the “target HLA” operationally, and align on test turnaround to avoid treatment delays. Payers will look for randomized evidence with a payer-relevant endpoint hierarchy and a clear companion diagnostic strategy, plus a cost position that justifies adding a vaccine to high-cost checkpoint backbones.
Competition is tightening. Beyond ipi-nivo and PD-1/LAG-3 combinations, the field is watching personalized neoantigen vaccines in adjuvant and advanced melanoma, including mRNA modalities in Phase 3 that promise strong efficacy but with bespoke manufacturing complexity. Scancell’s pitch is the opposite: an off-the-shelf DNA construct targeting shared antigens across common HLA alleles, which could scale more simply and economically if efficacy holds. That differentiation will be stress-tested as payers compare outcomes, toxicity, and total cost of care across vaccine classes and checkpoint doublets.
The company’s broader platform move adds optionality. Early Modi-1 signals in head and neck cancer and an ongoing renal cell carcinoma cohort extend the thesis into additional solid tumors, while the Genmab agreements, with upfronts and substantial milestones plus low single-digit royalties, offer a secondary funding spine and external development muscle. Creating GlyMab Therapeutics as a wholly owned subsidiary sharpens asset visibility for future partnering or spin-outs, a structure increasingly adopted by biotechs seeking financing flexibility without diluting core clinical programs. With £16.9 million in cash as of April 30, 2025, and runway into the second half of 2026, Scancell has a window to deliver confirmatory readouts and finalize pivotal design, but capital markets or partnerships will likely determine the pace.
The next 12 months will be decisive: additional SCOPE data, initial readout from the accelerated immunization cohort with intradermal delivery, and Modi-1 combinations in RCC could shape regulatory dialogue ahead of 2026 trial starts. The strategic test is clear: can Scancell secure the right partner and design a biomarker-led, globally acceptable pivotal program fast enough to outmaneuver mRNA rivals and evolving PD-1/LAG-3 regimens—and can it propose a price-to-value story that convinces payers a vaccine add-on is the new checkpoint baseline rather than a premium luxury?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
